The use of this medicine, which contains Interferon Alfa-2b, is based on established therapeutic guidelines. It is commonly used to support patients facing active chronic viral hepatitis B and C, as well as in the management of select cancers like Hairy Cell Leukemia, Follicular Non-Hodgkin's Lymphoma, AIDS-related Kaposi's Sarcoma, and as supportive therapy for high-risk Malignant Melanoma after surgery. The medicine is also applied to address the manifestations of localized viral growths, specifically Condylomata Acuminata.

“The therapy is relevant for easing the overall symptom burden associated with chronic viral activity or specific conditions where cell growth is a factor.”

In chronic viral settings, the application is relevant for easing the overall burden of the infection by aiming to inhibit viral replication and assisting with the symptomatic management that targets measurable viral markers. This action supports the patient in managing long-term health challenges associated with the condition. In oncology, the supportive approach helps manage the tumor burden and assists with managing symptoms that interfere with daily functioning.

Quick Fact: Relief for Viral and Neoplastic Strain
This medicine is commonly used to help patients manage conditions characterized by heightened physiological strain from persistent viral activity or the uncontrolled proliferation of cells, supporting functional stability.

Official Eligibility Rules and Contraindications

Бинноферон альфа (Interferon Alfa-2b) is restricted by regulatory labeling based on a patient’s medical history and existing conditions.

Contraindicated Populations (Must Not Use)	Age-Related Eligibility Rules
Autoimmune Hepatitis or Decompensated Liver Disease (Child-Pugh B or C).	Pediatric Use (Hepatitis B): Approved for patients ge 1 year of age.
History of Severe Psychiatric Disorders (e.g., severe depression, suicidal ideation).	Pediatric Use (Hepatitis C): Approved for patients ge 3 years (in combination).
Severe Pre-existing Cardiovascular Disease (e.g., uncontrolled heart failure).	Use Not Established: Safety and efficacy are not established for non-viral indications in patients under 18.
End-Stage Renal Disease (GFR <15 mL/min).	Geriatric Use: Caution is advised due to the higher likelihood of pre-existing organ dysfunction.

Eligibility is also defined by reproductive status. When used in combination with ribavirin, the medicine is absolutely contraindicated in pregnant women and in male partners of pregnant women. Monotherapy use during pregnancy is restricted to cases where the benefit outweighs the risk, and effective contraception is required for females of reproductive potential. For breastfeeding, regulatory documents state it is unknown if the substance is excreted into human milk.

Interactions with other medicines and products

The interaction profile of Бинноферон альфа, which contains Interferon Alfa-2b human recombinant, is defined by documented pharmacokinetic and pharmacodynamic effects with other substances, as detailed in regulatory labeling.

Contraindicated Combinations and Restrictions

Co-administration with Fezolinetant is formally contraindicated due to the potential for a significant increase in its plasma concentration resulting from metabolic inhibition. Furthermore, the combination therapy involving Ribavirin is restricted, being contraindicated in specific patient populations, including those with severe renal impairment (Creatinine clearance less than 50 mL/min) and patients with pre-existing hemoglobinopathies.

Pharmacokinetic and Exposure Alterations

Interferon Alfa-2b is documented to suppress the activity of hepatic CYP450 enzymes. This mechanism results in the decreased metabolism and subsequent increased plasma exposure of co-administered drugs that are substrates for these enzymes. This effect is formally noted with substances such as Theophylline and Zidovudine, where clearance is reduced. The potential for this interaction with Theophylline is noted to be greater in smokers.

Pharmacodynamic Risks

Additive effects are documented when Бинноферон альфа is used alongside certain classes of medicines. This includes an increased risk of excessive myelosuppression when combined with other myelosuppressive agents. Additive effects on the central nervous system (CNS) are also noted with narcotics, hypnotics, or sedatives. The official labeling also states that the anticoagulant effect of Warfarin is increased.

Бинноферон альфа is a recombinant protein that acts as an agonist for specific cell surface receptors. Its primary biological targets are the transmembrane receptor complexes, specifically the Interferon Alpha/Beta Receptors, IFNAR1 and IFNAR2, present across various immune and target cells. This interaction initiates an immediate intracellular signaling cascade.

The binding of Бинноферон альфа causes the activation and subsequent phosphorylation of associated Janus Kinase (JAK) family members, primarily JAK1 and Tyk2. These activated kinases create docking sites for Signal Transducers and Activators of Transcription (STAT) proteins, mainly STAT1 and STAT2, which also become phosphorylated.

Activated STAT heterodimers then translocate into the nucleus and bind to Interferon-Stimulated Response Elements (ISREs) in the genome. This pathway modulation leads to the transcriptional upregulation of hundreds of Interferon-Stimulated Genes (ISGs). The resultant expression of ISG-encoded proteins mediates a system-level physiological consequence by establishing an antiviral state within cells and modulating various innate and adaptive immune cell functions, such as enhancing natural killer (NK) cell activity.

Бинноферон альфа is administered exclusively through injection, as the protein structure of the active ingredient, Interferon Alfa-2b, requires parenteral delivery to ensure systemic absorption and biological effect. The official usage instructions define four primary routes of administration: subcutaneous (SC) and intramuscular (IM) injection are utilized for maintenance and general use, while specific localized conditions may require intralesional (IL) injection. A controlled intravenous (IV) infusion is reserved for certain high-dose induction regimens.

Usage is governed by precise, standardized dosage schedules. The exact amount administered is often calculated based on the patient’s body surface area (IU/m^2) for high-dose protocols, or as fixed International Unit (IU) doses for other regimens. The frequency pattern is typically intermittent, such as three times per week for many maintenance protocols, or daily for five consecutive days during certain induction cycles. Established dosing regimens, based on IU/m^2, are also detailed within the official labeling for pediatric patients.

Administration requires strict adherence to procedural conditions. For SC and IM injections, the site must be rotated to conform to proper usage standards. If the medicine is supplied as a lyophilized powder, it must be carefully reconstituted with the designated sterile diluent prior to use. IV administration must be conducted as a fixed 20-minute infusion. If a scheduled dose is missed, it is administered as soon as it is remembered, then the subsequent dose is adjusted to ensure a 48-hour interval is maintained. These established instructions define the standardized approach to using the medicine.

Research evidence / Overview of Studies for Бинноферон альфа

---

Evidence for Use in Chronic Viral Hepatitis

Research exploring the use of Бинноферон альфа was studied for its impact in conditions characterized by systemic or functional imbalance related to viral activity and liver health. These trials include both Randomized Controlled Trials (RCTs) and larger multicenter clinical studies. The studies typically involved adults and, in some cases, children, monitoring outcomes such as changes in viral genetic material and the normalization of certain liver enzyme levels over defined time intervals. Findings describe patterns observed in these studies, where some patients showed changes measured during the study period, such as changes related to viral markers. What remains uncertain is the long-term stability of these measured changes, as data for durability of response lasting many years are still emerging.

---

Evidence for Use in Hairy Cell Leukemia

The evidence base for this condition, characterized by functional limitations related to blood cell counts, consists of multicenter trials and extended long-term follow-up studies. Researchers explored outcomes related to objective response rates and the measured shifts in key blood cell counts. The studies reported that a large proportion of the observed populations achieved measurements consistent with a change in their blood counts. Research consistently documents that a portion of patients whose disease was studied for patterns of return of activity over time. Additionally, the existing research provides limited comparative evidence against newer targeted therapies.

---

Evidence for Use in High-Risk Malignant Melanoma

Бинноферон альфа was studied for use in the adjuvant setting—meaning after a high-risk melanoma tumor has been surgically removed. The primary study type was Randomized Phase III Trials which examined outcomes by tracking measurements related to the recurrence-free period and overall survival over long follow-up durations. Research highlights that patterns observed in the studies included measurements related to the recurrence-free period compared to control groups. However, systematic reviews documented that the findings were mixed regarding the measurements for Overall Survival across different trials. The key research limitations are that the evidence quality varies across studies due to differences in the specific requirements for dose and schedules used.

---

What is Still Uncertain About the Research Base

Scientific evidence highlights what is known—and what is still uncertain—about Бинноферон альфа. The main areas of uncertainty include: the research requirements for dose and duration for high-risk melanoma, where findings were mixed regarding overall survival; comparative evidence is lacking against newer, more targeted therapies now available for certain cancers; and recurrence is a common pattern observed in trials for many indications once the treatment period concludes. The research provides insight into short-term changes, but due to variability across studies and modest sample sizes in certain subgroups, certainty remains low for many long-term outcome predictions.

Common questions about Бинноферон альфа (FAQ)

Q: What is the main reason doctors prescribe Бинноферон альфа?

A: Official regulatory documents state that the medicine is approved for specific conditions. These indications include chronic viral hepatitis B and C, as well as certain types of cancer, such as Hairy Cell Leukemia and high-risk malignant melanoma.

Q: Is there a maximum time someone can take Бинноферон альфа according to official guidance?

A: Official guidance on the duration of treatment varies significantly based on the condition being addressed. Some protocols may involve a short induction phase followed by approximately a year of maintenance treatment, while other conditions may require therapy lasting up to 18 to 24 months.

Q: Does the official information mention if Бинноферон альфа interacts with common pain relievers?

A: The official patient information often refers to the use of common pain relievers. This is because non-prescription pain relievers like acetaminophen or ibuprofen are commonly used to help manage the flu-like symptoms, such as fever and headache, which are the most frequent side effects.

Q: Are there different strengths of Бинноферон альфа available?

A: Yes, the medicine is manufactured and supplied in different strengths. These strengths are measured in International Units ( IU), with various dose levels available, such as 1 million IU up to 50 million IU per milliliter, depending on the formulation.

Q: Is Бинноферон альфа a biologic drug?

A: Yes, the product is generally classified as a biologic medicine. This classification is due to the active ingredient, Interferon Alfa-2b, being a recombinant protein—a complex molecule engineered in a laboratory setting.

Q: Does the official guidance describe any known interactions between Бинноферон альфа and alcohol?

A: Official patient guidance often includes a precaution against alcohol consumption, noting that alcohol can potentially increase the severity of certain side effects, such as confusion, lightheadedness, or dizziness.

Q: What does 'contraindication' mean in the context of Бинноферон альфа?

A: In the context of this medicine, a contraindication is an official statement that describes a specific medical condition or factor that prevents the drug from being used. Official guidance specifies that the medicine must not be used by patients who have conditions such as severe psychiatric disorders or decompensated liver disease.

Q: Does the effectiveness of Бинноферон альфа depend on when you start using it?

A: For certain conditions, official documentation suggests the timing of when the medicine is started is a critical factor in its use. For example, when used for malignant melanoma, the regulatory label indicates it must be started as an adjuvant therapy—that is, within a specific timeframe following surgery.

Q: Is it possible for the official side effect list for Бинноферон альфа to change over time?

A: Yes, the official list of side effects in a drug’s regulatory label is considered a dynamic document. Regulatory authorities worldwide require continuous monitoring and reporting of new safety information, which can lead to formal updates or changes to the list of known effects over time.

Q: Is Бинноферон альфа a drug that has been used for a long time?

A: The active substance in the medicine, Interferon Alfa-2b, has been used clinically to treat various diseases for a long period. Official records indicate that the original regulatory approvals for this type of product date back to the late 1980s or early 1990s in many countries.

Q: What does the research say about stopping Бинноферон альфа suddenly?

A: Regulatory documents outline specific criteria for when the drug should be discontinued by a healthcare provider. These instructions describe conditions such as failure of the disease to respond to treatment or the recurrence of severe adverse reactions (toxicity) that would necessitate stopping the medicine.

Q: Does the official document describe any specific signs of a serious allergic reaction?

A: Official patient literature describes signs to watch for that may indicate a serious allergic reaction. These signs include difficulty breathing, shortness of breath, the development of rash or hives, and swelling of the throat, lips, or face.

Q: Can the drug be safely used by people who have diabetes?

A: Regulatory information advises that people who have diabetes should use the medicine with caution. Official information notes that this medicine may affect blood sugar levels, and therefore close monitoring of blood glucose may be indicated during treatment.

Q: What are the ingredients in Бинноферон альфа besides the main active substance?

A: Besides the active substance, the official documentation lists inactive ingredients, or excipients, used in the final product. These typically include water for injection, various salts to help stabilize the formulation, and sometimes a preservative like Benzyl Alcohol, depending on the specific product form.

Q: Do official sources describe how to handle a potential overdose of Бинноферон альфа?

A: Official documentation describes management for severe side effects, or toxicity, which would apply in the event of an accidental overdose. Management focuses on treating the symptoms, which may involve temporarily withholding the drug or permanently stopping its use if severe reactions are experienced.

Q: Does the drug's official information include warnings about driving or operating machinery?

A: Official warnings advise that patients who experience side effects such as confusion, dizziness, visual problems, or somnolence (drowsiness) may need to avoid driving or operating machinery.

Q: Why are some dosage forms of Бинноферон альфа meant for different age groups?

A: The reason for different approved age groups for the medicine is based on specific clinical trials. Regulatory bodies review these studies, which are conducted separately to establish the safety and effectiveness for each disease and population, resulting in different age-related approvals for various uses.

Q: Are there specific laboratory tests recommended while using Бинноферон альфа?

A: Yes, regulatory information recommends monitoring certain laboratory parameters before and during treatment. These often include the Complete Blood Count ( CBC), platelet counts, Liver Function Tests ( LFTs), and Thyroid-Stimulating Hormone ( TSH).

Q: Does the official documentation mention any impact on fertility?

A: Official safety data sheets include hazard statements indicating that the medicine may potentially damage fertility. This statement is based on required studies to determine the reproductive safety profile of the substance.

Q: What is the shelf life of the drug before it is opened?

A: The official shelf life for the unopened product, particularly the lyophilized (powder) form, is typically 24 months. This stability depends on strictly following the mandatory refrigerated storage conditions (between 2 C and 8 C).

Q: What kind of specialist typically prescribes Бинноферон альфа?

A: Given the serious nature of the approved conditions (such as specific cancers and chronic viral infections), the medicine is typically prescribed and monitored by medical specialists. These commonly include oncologists, hematologists, or infectious disease experts.

Q: Does the official information mention if this medicine causes drowsiness?

A: Although drowsiness, or somnolence, is not listed among the most frequent side effects, it is a recognized adverse reaction in the official documents. The possibility of drowsiness is mentioned specifically in the safety warnings regarding driving and operating heavy machinery.

Q: Is there a generic version of Бинноферон альфа available?

A: The original branded version of the active ingredient, Interferon Alfa-2b, has been discontinued by some manufacturers in various regions. A lower-cost generic equivalent is generally not available because the product is a complex biologic medicine that requires a different regulatory pathway for approval.

The official regulatory requirements for storing this Interferon Alfa-2b product mandate strict refrigeration. The medicine must be stored between 2 C and 8 C (36 F and 46 F) and must not be frozen. To maintain stability, the vials or syringes must be kept in the original outer carton to protect them from light and heat.

After preparation or opening, the solution has a limited stability period and any unused portion from single-dose containers must be discarded immediately. All medicine, including used needles and syringes, must be kept out of the sight and reach of children. Disposal of used needles and sharps must be done using an approved, puncture-resistant container, with the final disposal following local government guidelines for medical waste.